NASDAQ
40.94USD
+0.36 (+0.89%)
We have scored 11 news catalysts on Vericel Corporation (VCEL) over the past 12 months. The biggest single-day move next to one of them came Apr 2, 2026, when VCEL closed +4.9%: “MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million”. Coverage across the window leans positive (average ticker sentiment +0.69). Most of the impact sits in forward growth expectations and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.1B
P/E
—
EPS
—
Beta
1.02
52W range
28.95-49.32
Day range
40.00–41.04
Open
40.00
Prev close
40.58
Volume
432K
Avg volume
555K
Dividend
0.00
IPO
1997-02-04
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Vericel Corporation — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for VCEL: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
